Weight loss interventions in womenparticularly postmenopausal womenare associated with changes in sex hormone profiles, including reductions in circulating oestrogens and changes in sex hormone-binding globulin in controlled trial settings
In a clinical trial published in 2023, the STEP-HFpEF trial, weekly injections of a standard dose of semaglutide significantly reduced symptoms in people with obesity and HFpEF, boosted their exercise capacity and improved their quality of life
Some prescribers may consider semaglutide for off-label use in people with overweight or obesity, insulin resistance, or metabolic syndrome when they judge it appropriate
The clinical evidence for these multi-additive combinations is limited, but anecdotal reports from providers and patients are generally positive
SGLT-2 inhibitors, medications like empagliflozin, dapagliflozin, and canagliflozin, work by blocking glucose reabsorption in the kidneys
Well talk about some basic exercises that you can try out in the next section
